Posted by Michael Wonder on 21 Dec 2022
ICER publishes evidence report on treatments for multiple sclerosis
21 December 2022 - Evidence is rated as insufficient to differentiate the net health benefit between ublituximab and other monoclonal antibodies; analyses suggest ublituximab and all currently available monoclonal antibodies labeled for multiple sclerosi would achieve common thresholds for cost effectiveness if priced between $16,500-$34,900 per year, a range far lower than current market prices net of all rebates.
The ICER today posted its revised Evidence Report assessing the comparative clinical effectiveness and value of multiple treatments for patients with multiple sclerosis.
